Stoke Therapeutics, Inc. (STOK)

Several events have impacted Stoke Therapeutics' stock price over the past six months. Stoke Therapeutics reported a Q1 2026 loss of $0.79 per share, topping estimates, but revenue of $6.23 million was below estimates, representing a significant decrease from the previous year due to a one-time Biogen license revenue. The Phase 3 data readout for zorevunersen (STK-001) for Dravet syndrome was delayed until mid-2027. Recent insider selling by the Chief Medical Officer and Chief Financial Officer further fueled investor worries. New 4-year longitudinal data from Phase 1/2a open-label extension studies provided additional support for zorevunersen. The first patient was dosed in the Phase 1 study of STK-002 for autosomal dominant optic atrophy. The company announced updates to timelines for the completion of enrollment and a Phase 3 data readout from the EMPEROR study of zorevunersen, with enrollment of 150 patients expected to complete in Q2 2026.

Information regarding specific demand seasonality for Stoke Therapeutics' products and services is not explicitly available. Demand for its product candidates, once approved, would likely be driven by the prevalence of the target diseases rather than typical seasonal fluctuations. The company's revenue currently relies on collaboration income, which can be lumpy and not subject to seasonality.

Stoke Therapeutics, Inc. is a biotechnology company focused on developing RNA-based medicines to treat severe genetic diseases by upregulating protein expression. Their proprietary TANGO approach is used to develop antisense oligonucleotides. Their lead product candidates include Zorevunersen (STK-001), in Phase 3 for Dravet syndrome, and STK-002, in Phase 1 for autosomal dominant optic atrophy. The company collaborates with Biogen Inc. for zorevunersen and Acadia Pharmaceuticals Inc. for rare genetic neurodevelopmental diseases. Stoke Therapeutics was founded in June 2014 and is headquartered in Bedford, MA.

Stoke Therapeutics, Inc. is headquartered in Bedford, Massachusetts, United States. Clinical trials for zorevunersen (STK-001) in Dravet syndrome are global, with enrollment expected to complete in the U.S., UK, and Japan in Q2 2026.

Stoke Therapeutics' brand reputation is tied to its clinical progress and financial performance. Positive impacts include the publication of data in The New England Journal of Medicine demonstrating the potential for disease modification in Dravet syndrome, along with durable seizure reductions and improvements in cognition and behavior from zorevunersen. Negative impacts include the recent delay in the Phase 3 data readout for zorevunersen and a significant revenue shortfall in Q1 2026, as well as insider selling by key executives.

Stoke Therapeutics, Inc. has a mixed ownership structure, including institutional, retail, and individual investors. As of May 4, 2026, there are 187 institutional owners holding a total of 68,694,473 shares. Major institutional owners include Fmr Llc, RTW Investments, LP, Lynx1 Capital Management LP, BlackRock, Inc., Redmile Group, LLC, Morgan Stanley, Baker Bros. Advisors Lp, Vanguard Group Inc and State Street Corp. Seth Loring Harrison is the largest individual shareholder, owning 33.95 million shares representing 54.51% of the company. Insiders collectively own approximately 34.68% of the company's stock.